mRNA Vaccines Targeting the Stable SARS-CoV-2 Fusion Proteins Produce Strong Immunity Against Multiple Variants

Two mRNA-lipid nanoparticle vaccines encoding a conserved immunogen were evaluated for their potential against SARS-CoV-2 variants.

• The S1 subunit of the spike protein has shown limited effectiveness against emerging viral variants.
• Conserved regions within the S2 fusion machinery may be critical targets for future vaccine development.
• The study compares the efficacy of mRNA-LNP vaccines with a recombinant HR121 protein vaccine.

Simplified